Inflammatory connective tissue diseases

Inflammatory connective tissue diseases (ICTDs) are a heterogeneous group of systemic autoimmune conditions characterised by immune-mediated inflammation affecting connective tissue throughout the body. The major ICTDs include systemic lupus erythematosus (SLE), systemic sclerosis (SSc), Sjögren syndrome (SjS), mixed connective tissue disease (MCTD), and the inflammatory myopathies (dermatomyositis, polymyositis, and antisynthetase syndrome). These conditions frequently overlap clinically and serologically, share pathogenic mechanisms, and often require similar multidisciplinary management approaches. ICTDs predominantly affect women of childbearing age and have significant morbidity and mortality.

ICTDs share common pathogenic mechanisms including dysregulated innate and adaptive immune activation, loss of self-tolerance, and autoantibody-mediated and cell-mediated tissue injury. Genetic susceptibility (particularly HLA associations), environmental triggers (UV light, infections, drugs, smoking), and hormonal factors (female predominance) interact to drive ICTD development.

Shared Pathogenic Mechanisms

• Type I interferon (IFN) pathway activation — central to SLE, dermatomyositis, SSc, and SjS; plasmacytoid dendritic cells and neutrophil extracellular traps (NETs) drive IFN production
• Loss of self-tolerance — failure of central and peripheral tolerance mechanisms leading to autoreactive T and B cell survival
• Autoantibody production — targeting nuclear antigens (ANA, anti-dsDNA), cytoplasmic antigens (anti-Jo-1, anti-Ro/SSA), and cell surface antigens
• Complement activation — immune complex deposition activates complement leading to tissue damage (most prominent in SLE nephritis)
• T cell dysregulation — Th17/Treg imbalance; CD4+ cytotoxic T cells in myositis and IgG4-RD
• Fibroblast activation — transforming growth factor-β (TGF-β) driven fibrosis central to SSc; also relevant in ILD across multiple ICTDs
• Vasculopathy — endothelial injury and dysfunction; Raynaud's phenomenon common to SSc, MCTD, SLE, and antisynthetase syndrome

Genetic and Environmental Factors

• HLA associations — HLA-DR2, DR3 (SLE); HLA-DR3, DR52 (SjS, antisynthetase); HLA-DR5, DR11 (SSc)
• Non-HLA genes — STAT4, IRF5, PTPN22, BLK polymorphisms shared across multiple ICTDs
• Environmental triggers — UV light (SLE, dermatomyositis); silica dust (SSc); Epstein-Barr virus (SLE, SjS)
• Hormonal factors — oestrogen promotes immune activation; explains female predominance and flare risk during pregnancy
• Smoking — associated with SSc, anti-CCP positive rheumatoid overlap, and SLE

ICTDs share several clinical features across conditions, and overlap syndromes are common. The key to diagnosis is systematic evaluation of clinical features combined with serological profiling.

Clinical Features Common to Multiple ICTDs

Overlap Syndromes

• Overlap syndromes are common — features of ≥2 defined CTDs coexist; SSc-myositis overlap, SLE-SjS overlap, and SSc-SjS overlap are most frequent
• Undifferentiated CTD (UCTD) — patients who have features consistent with a CTD and positive ANA but do not meet classification criteria for any specific CTD; many eventually evolve to a defined ICTD over 3–5 years
• Mixed connective tissue disease (MCTD) — defined overlap with features of SLE, SSc, and myositis + very high titre anti-U1 RNP; often considered a distinct entity
• Antisynthetase syndrome — features of myositis + ILD + arthritis + mechanic's hands + Raynaud's + anti-aminoacyl-tRNA synthetase antibodies; may overlap with polymyositis/dermatomyositis

Autoantibody profiling is central to ICTD diagnosis, subtype classification, and monitoring. The ANA is the screening test for most ICTDs; a positive ANA with a titre ≥1:160 warrants further specific antibody testing. However, a low-titre positive ANA is common in the general population and is non-specific.

Autoantibody Profile in ICTDs

• Essential
  ANA (indirect immunofluorescence, HEp-2 cells)

  Screening for all ICTDs. If positive at ≥1:160, proceed to specific antibody testing. Pattern (homogeneous, speckled, nucleolar, centromere) guides next test selection.
• Essential
  ENA panel (anti-dsDNA, anti-Sm, anti-Ro/SSA, anti-La/SSB, anti-U1 RNP, anti-Scl-70, anti-Jo-1)

  Extractable nuclear antigen panel — performed if ANA positive or ICTD suspected on clinical grounds. Guides specific diagnosis and monitoring.
• Essential
  FBC, UEC, LFTs, CRP, ESR

  Baseline; assess organ involvement, cytopenias, renal impairment. CRP is often low-normal in SLE flare (unlike bacterial infection or RA).
• Essential
  Urinalysis and urine protein:creatinine ratio

  Screen for nephritis — haematuria, proteinuria, red cell casts. Required at every visit in SLE.
• Essential
  Complement C3, C4, CH50

  Consumed in SLE nephritis and other immune complex-mediated disease. Low C4 may indicate complement deficiency predisposing to SLE.
• Recommended
  MSA/MAA panel (if myositis suspected)

  Anti-Jo-1, anti-MDA5, anti-TIF1γ, anti-NXP2, anti-Mi-2, anti-Ro52, anti-U1RNP. Guides myositis subtype, ILD risk, and malignancy risk.
• Recommended
  Anti-phospholipid antibody panel

  Lupus anticoagulant, anti-cardiolipin (IgG/IgM), anti-β2-glycoprotein I (IgG/IgM). Confirm positive result ≥12 weeks apart.
• Recommended
  HRCT chest

  Assess for ILD — baseline in SSc, antisynthetase, MCTD; when respiratory symptoms in any ICTD. Also screen for malignancy in high-risk DM (anti-TIF1γ).
• Recommended
  Nailfold capillaroscopy

  Abnormal in SSc (giant loops, avascular areas) and MCTD. Helps distinguish primary from secondary Raynaud's. Guides SSc subset classification.
• Recommended
  Echocardiogram

  Pulmonary hypertension screening — mandatory in SSc (annually); assess in MCTD, SLE. Pericardial effusion in SLE/RA.

Risk stratification in ICTDs identifies patients at highest risk of organ damage, malignancy, complications of treatment, and death.

Treatment of ICTDs is tailored to disease activity, organ involvement, and comorbidities. Hydroxychloroquine is a cornerstone of therapy across multiple ICTDs. Glucocorticoids provide rapid disease control but have significant long-term toxicity. Steroid-sparing agents are essential for long-term management. All patients with ICTD should be managed in collaboration with a rheumatologist.

Agents Used Across Multiple ICTDs

Biologic Agents in ICTDs

• Belimumab (anti-BAFF) — PBS-listed for active SLE; reduces flare rate and organ damage; given IV monthly or SC weekly; not for active nephritis or CNS lupus at initiation
• Rituximab (anti-CD20) — used in refractory SLE, IIM, SjS, MCTD, SSc-ILD; strong evidence in myositis and IgG4-RD; PBS access for SLE limited
• Voclosporin or tacrolimus — calcineurin inhibitors used in lupus nephritis; voclosporin PBS-listed for lupus nephritis in combination with MMF
• Nintedanib / pirfenidone — antifibrotic agents for SSc-ILD; nintedanib PBS-listed for SSc-ILD
• Bosentan / ambrisentan / sildenafil — pulmonary arterial hypertension agents in SSc, MCTD, SLE-PAH

Directed therapy in ICTDs addresses specific organ manifestations that require targeted approaches beyond systemic immunosuppression.

Interstitial Lung Disease (ILD) in CTDs

• Baseline HRCT and PFTs (FVC, DLCO) in all patients with SSc, antisynthetase syndrome, MCTD, and symptomatic IIM
• Treatment guided by HRCT pattern (NSIP most common in CTD-ILD; UIP pattern worse prognosis), extent, and rate of progression
• First-line: MMF or azathioprine ± prednisolone; rituximab for refractory cases
• Antifibrotic therapy (nintedanib) for SSc-ILD and progressive fibrotic ILD — can be combined with MMF
• Pulmonary rehabilitation — all patients with symptomatic ILD
• Pulmonology co-management for all CTD-ILD

Pulmonary Arterial Hypertension (PAH)

• Screen annually with echocardiogram in SSc and MCTD; right heart catheterisation to confirm
• PAH-specific therapy: phosphodiesterase-5 inhibitors (sildenafil, tadalafil), endothelin receptor antagonists (bosentan, ambrisentan), prostacyclin analogues
• Specialist PAH centre referral for all confirmed CTD-PAH

Raynaud's Phenomenon

• Non-pharmacological: cold avoidance, heated gloves, stress management, smoking cessation
• First-line pharmacological: dihydropyridine calcium channel blockers (nifedipine, amlodipine)
• Severe/digital ulcers: IV iloprost; bosentan for recurrent digital ulcers in SSc; phosphodiesterase-5 inhibitors

Pregnancy in ICTDs

• All ICTDs carry increased pregnancy risk — pre-conception counselling essential
• Disease should be in remission for ≥6 months before conception (especially SLE nephritis)
• Compatible medications: hydroxychloroquine, azathioprine, low-dose prednisolone, low-dose aspirin (APS)
• Contraindicated in pregnancy: MTX, MMF, belimumab, cyclophosphamide — must be stopped ≥3 months before conception
• Anti-Ro/SSA positive mothers: fetal heart rate monitoring for congenital heart block from 16 weeks
• Antiphospholipid antibodies: LMWH + aspirin for high-risk obstetric APS

Non-pharmacological management is integral to ICTD care — addressing cardiovascular risk, photoprotection, vaccination, bone health, and psychosocial support.

Sun Protection and Lifestyle

• Photoprotection — SPF 50+ sunscreen daily, UV-protective clothing, sun avoidance during peak hours; essential for SLE, dermatomyositis, subacute cutaneous SLE, SjS
• Smoking cessation — reduces flare risk (SLE), ILD progression (SSc), and cardiovascular risk
• Cold avoidance and hand warming — Raynaud's management; heated gloves, mittens, hand warmers
• Regular exercise — maintains muscle strength and cardiovascular fitness; adapt to individual capacity

Cardiovascular Risk Reduction

• ICTD patients have significantly elevated cardiovascular risk — chronic inflammation accelerates atherosclerosis
• Annual lipid profile, blood pressure, and glucose monitoring
• Statin therapy — indicated by standard cardiovascular risk score; lower threshold in SLE
• Hydroxychloroquine has mild protective cardiovascular effects in SLE

Bone Health and Corticosteroid Management

• Calcium 600–1200 mg/day + vitamin D 1000–2000 IU/day — all patients on corticosteroids
• Bisphosphonate therapy — osteoporosis prevention for prolonged corticosteroid use
• DXA bone density — baseline and annually for prolonged steroid exposure

Vaccination

• Annual influenza vaccine — all ICTD patients on immunosuppression
• Pneumococcal vaccine (13-valent + 23-valent) — all patients on significant immunosuppression
• Herpes zoster vaccine (recombinant, non-live Shingrix) — recommended for patients ≥50 years or on immunosuppression
• COVID-19 vaccination — recommended for all ICTD patients; discuss timing relative to rituximab cycles with rheumatologist
• Live vaccines contraindicated on significant immunosuppression (cyclophosphamide, rituximab, high-dose steroids)

Psychosocial Support

• Chronic illness burden — fatigue, pain, altered appearance, and treatment side effects significantly impact quality of life
• Psychology referral — for anxiety, depression, coping strategies, and chronic pain management
• Patient support organisations — Lupus Australia, Arthritis Australia — peer support and disease education
• Occupational therapy — workplace adaptations, energy conservation strategies

Monitoring in ICTDs is directed by the specific condition, organ involvement, and medications used. The following table summarises shared monitoring requirements.

When to Refer

• Rheumatology: All suspected or confirmed ICTDs — diagnosis, treatment initiation, and ongoing management coordination
• Nephrology: Lupus nephritis; renal impairment in any ICTD
• Pulmonology: ILD; PAH workup; respiratory muscle weakness
• Cardiology: PAH; pericardial disease; myocarditis
• Dermatology: Complex or refractory skin disease
• Ophthalmology: Annual HCQ monitoring; ocular sicca; scleritis/episcleritis
• Obstetrics/maternal-fetal medicine: Pre-conception counselling and pregnancy management
• Psychology: Depression, anxiety, chronic pain

Several patient groups with ICTDs require modified diagnostic and management approaches.

Undifferentiated CTD (UCTD)

• Positive ANA + ≥1 ICTD feature but criteria for specific diagnosis not met — diagnose as UCTD
• ~30–40% evolve to a defined ICTD over 5 years — SSc, SLE, and SjS most common
• Treat symptomatically; hydroxychloroquine for constitutional symptoms and arthralgia
• 6-monthly rheumatology review — monitor for new features indicating evolution to specific ICTD
• Anti-Ro/SSA, anti-U1 RNP, ACA, anti-Scl-70 positive UCTD has higher risk of progression

Male Patients with ICTD

• ICTD less common in males — diagnosis may be delayed due to lower clinical suspicion
• SLE in males is often more severe — higher rates of nephritis and neuropsychiatric disease
• Malignancy risk in male DM is higher — thorough malignancy screen at diagnosis

Elderly-Onset ICTD

• Late-onset SLE — often Ro-positive; less nephritis; more serositis and sicca features; drug-induced lupus must be excluded
• Higher comorbidity burden — polypharmacy, renal impairment, bone fragility; adjust immunosuppression doses
• Infection risk is higher — minimise cumulative glucocorticoid exposure; PCP prophylaxis if high-dose combination immunosuppression

Drug-Induced Lupus

• Common causative drugs: hydralazine, procainamide, isoniazid, minocycline, anti-TNF biologics, checkpoint inhibitors
• Anti-histone antibodies — characteristic of drug-induced lupus (absent in idiopathic SLE)
• Resolves on drug cessation — usually within weeks to months; rarely requires immunosuppression

Stewardship in ICTDs focuses on minimising glucocorticoid toxicity, ensuring appropriate use of immunosuppressants, and coordinating care across disciplines.

GP Role

• Suspect ICTD in a young woman with unexplained multisystem symptoms — fatigue, arthralgia, rash, Raynaud's, oral ulcers, alopecia, sicca symptoms
• Initial screen: ANA, ENA, FBC, UEC, LFTs, CRP, ESR, urinalysis, complement (C3, C4), anti-dsDNA
• Urgent rheumatology referral — do not delay for diagnosis confirmation if organ-threatening features present (nephritis, serositis, cytopenias)
• Hydroxychloroquine can be initiated by GP for SLE arthralgia/skin disease pending rheumatology review
• Coordinate long-term monitoring of corticosteroid complications — bone density, glucose, BP, ophthalmology
• Ensure vaccinations are up to date before immunosuppression
• Monitor for flares and medication side effects — liaise promptly with rheumatologist for escalation

ICTDs require indefinite long-term follow-up. Disease activity fluctuates, and new organ manifestations can develop years after diagnosis. The goal is to maintain remission at the lowest possible immunosuppressive burden.

Remission and Treatment Goals

• Target: remission or lowest possible disease activity on minimum effective treatment — "treat-to-target" strategy endorsed for SLE and applies broadly to ICTDs
• Hydroxychloroquine should be continued indefinitely in SLE — stopping increases flare and damage risk
• Organ damage accrual — damage is cumulative and largely irreversible; preventing flares prevents damage
• Transition of care — young adult patients with paediatric-onset disease require planned transition to adult rheumatology

• 01
  Fanouriakis A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
• 02
  Distler O, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380(26):2518–2528.
• 03
  Shiboski CH, et al. 2016 ACR/EULAR classification criteria for primary Sjögren's syndrome. Arthritis Rheumatol. 2017;69(1):35–45.
• 04
  van den Hoogen F, et al. 2013 classification criteria for systemic sclerosis. Ann Rheum Dis. 2013;72(11):1747–1755.
• 05
  Aringer M, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 2019;71(9):1400–1412.
• 06
  Therapeutic Guidelines. Rheumatology. Melbourne: Therapeutic Guidelines Ltd; 2024.
• 07
  Pharmaceutical Benefits Scheme (PBS). Schedule of Pharmaceutical Benefits. Canberra: Department of Health; 2025.
• 08
  Royal Australian College of General Practitioners (RACGP). Clinical guidance — connective tissue diseases. Melbourne: RACGP; 2023.